Conditional inactivation of the mouse von Hippel-Lindau tumor suppressor gene results in wide-spread hyperplastic, inflammatory and fibrotic lesions in the kidney

Oncogene

Volumn 34, Issue 20, 2015, Pages 2631-2639

  Pritchett, T L ^a   Bader, H L ^a   Henderson, J ^a   Hsu, T ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CENTRAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HIF1A PROTEIN, MOUSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; JAK1 PROTEIN, MOUSE; JAK2 PROTEIN, MOUSE; JANUS KINASE 1; JANUS KINASE 2; VHLH PROTEIN, MOUSE; VON HIPPEL LINDAU PROTEIN;

ANIMAL; FIBROSIS; GENETICS; HUMAN; HYPERPLASIA; KIDNEY; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; MOUSE; MUTATION; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; CARCINOMA, RENAL CELL; FIBROSIS; HUMANS; HYPERPLASIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; JANUS KINASE 1; JANUS KINASE 2; KIDNEY; KIDNEY NEOPLASMS; MICE; MICE, TRANSGENIC; MUTATION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84939872439     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.197     Document Type: Article

References (54)

1. Frew IJ, Krek W. Pvhl: A multipurpose adaptor protein. Sci Signal 2008; 1: Pe30.
2. Hsu T. Complex cellular functions of the von hippel-lindau tumor suppressor gene: Insights from model organisms. Oncogene 2012; 31: 2247-2257.
3. Kaelin Jr WG. Treatment of kidney cancer: Insights provided by the vhl tumorsuppressor protein. Cancer 2009; 115: 2262-2272.
4. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML et al. Identification of the von hippel-lindau disease tumor suppressor gene. Science 1993; 260: 1317-1320.
5. Maher ER, Neumann HP, Richard S. Von hippel-lindau disease: A clinical and scientific review. Eur J Hum Genet 2011; 19: 617-623.
6. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S et al. Silencing of the vhl tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994; 91: 9700-9704.
7. Kim WY, Kaelin WG. Role of vhl gene mutation in human cancer. J Clin Oncol 2004; 22: 4991-5004.
8. Kaelin Jr WG. The von hippel-lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 2008; 8: 865-873.
9. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M et al. Hifalpha targeted for vhl-mediated destruction by proline hydroxylation: Implications for o2 sensing. Science 2001; 292: 464-468.
10. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: The central role of the hif hydroxylase pathway. Mol Cell 2008; 30: 393-402.
11. Rankin EB, Tomaszewski JE, Haase VH. Renal cyst development in mice with conditional inactivation of the von hippel-lindau tumor suppressor. Cancer Res 2006; 66: 2576-2583.
12. Frew IJ, Minola A, Georgiev S, Hitz M, Moch H, Richard S et al. Combined vhlh and pten mutation causes genital tract cystadenoma and squamous metaplasia. Mol Cell Biol 2008; 28: 4536-4548.
13. Ozcan A, Zhai J, Hamilton C, Shen SS, Ro JY, Krishnan B et al. Pax-2 in the diagnosis of primary renal tumors: Immunohistochemical comparison with renal cell carcinoma marker antigen and kidney-specific cadherin. Am J Clin Pathol 2009; 131: 393-404.
14. Kraus S, Abel PD, Nachtmann C, Linsenmann HJ, Weidner W, Stamp GW et al. Muc1 mucin and trefoil factor 1 protein expression in renal cell carcinoma: Correlation with prognosis. Hum Pathol 2002; 33: 60-67.
15. Khurana KK, Truong LD, Verani RR. Image analysis of proliferating cell nuclear antigen expression and immunohistochemical profiles in renal cell carcinoma associated with acquired cystic kidney disease: Comparison with classic renal cell carcinoma. Mod Pathol 1998; 11: 339-346.
16. Shen SS, Krishna B, Chirala R, Amato RJ, Truong LD. Kidney-specific cadherin, a specific marker for the distal portion of the nephron and related renal neoplasms. Mod Pathol 2005; 18: 933-940.
17. Srinivas S, Goldberg MR, Watanabe T, D'Agati V, al-Awqati Q, Costantini F. Expression of green fluorescent protein in the ureteric bud of transgenic mice: A new tool for the analysis of ureteric bud morphogenesis. Dev Genet 1999; 24: 241-251.
18. Yu J, Carroll TJ, McMahon AP. Sonic hedgehog regulates proliferation and differentiation of mesenchymal cells in the mouse metanephric kidney. Development 2002; 129: 5301-5312.
19. Zhao H, Kegg H, Grady S, Truong HT, Robinson ML, Baum M et al. Role of fibroblast growth factor receptors 1 and 2 in the ureteric bud. Dev Biol 2004; 276: 403-415.
20. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM et al. Hif activation identifies early lesions in vhl kidneys: Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002; 1: 459-468.
21. Kramann R, Dirocco DP, Humphreys BD. Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease. J Pathol 2013; 231: 273-289.
22. Nakagawa N, Duffield JS. Myofibroblasts in fibrotic kidneys. Curr Pathobiol Rep 2013; 1: 189-198.
23. Ries C. Cytokine functions of timp-1. Cell Mol Life Sci 2014; 71: 659-672.
24. Becker LC. Yin and yang of mcp-1. Circ Res 2005; 96: 812-814.
25. Perrier S, Darakhshan F, Hajduch E. Il-1 receptor antagonist in metabolic diseases: Dr jekyll or mr hyde? FEBS Lett 2006; 580: 6289-6294.
26. Quintas-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA et al. Preclinical characterization of the selective jak1/2 inhibitor incb018424: Therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010; 115: 3109-3117.
27. Wadleigh M, Tefferi A. Preclinical and clinical activity of atp mimetic jak2 inhibitors. Clin Adv Hematol Oncol 2010; 8: 557-563.
28. Shay JE, Celest Simon M. Hypoxia-inducible factors: Crosstalk between inflammation and metabolism. Semin Cell Dev Biol 2012; 23: 389-394.
29. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL et al. Contrasting properties of hypoxia-inducible factor 1 (hif-1) and hif-2 in von hippel-lindauassociated renal cell carcinoma. Mol Cell Biol 2005; 25: 5675-5686.
30. Martelli F, Ghinassi B, Panetta B, Alfani E, Gatta V, Pancrazzi A et al. Variegation of the phenotype induced by the gata1low mutation in mice of different genetic backgrounds. Blood 2005; 106: 4102-4113.
31. Yoshida N, Ikemoto S, Narita K, Sugimura K, Wada S, Yasumoto R et al. Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. Br J Cancer 2002; 86: 1396-1400.
32. An J, Rettig MB. Mechanism of von hippel-lindau protein-mediated suppression of nuclear factor kappa b activity. Mol Cell Biol 2005; 25: 7546-7556.
33. Yang H, Minamishima YA, Yan Q, Schlisio S, Ebert BL, Zhang X et al. Pvhl acts as an adaptor to promote the inhibitory phosphorylation of the nf-kappab agonist card9 by ck2. Mol Cell 2007; 28: 15-27.
34. Wu KL, Miao H, Khan S. Jak kinases promote invasiveness in vhl-mediated renal cell carcinoma by a suppressor of cytokine signaling-regulated, hif-independent mechanism. Am J Physiol Renal Physiol 2007; 293: F1836-F1846.
35. Brukamp K, Jim B, Moeller MJ, Haase VH. Hypoxia and podocyte-specific vhlh deletion confer risk of glomerular disease. Am J Physiol Renal Physiol 2007; 293: F1397-F1407.
36. Steenhard BM, Isom K, Stroganova L St, John PL, Zelenchuk A, Freeburg PB et al. Deletion of von hippel-lindau in glomerular podocytes results in glomerular basement membrane thickening, ectopic subepithelial deposition of collagen {alpha}1{alpha}2{alpha}1(iv), expression of neuroglobin, and proteinuria. Am J Pathol 2010; 177: 84-96.
37. Kimura K, Iwano M, Higgins DF, Yamaguchi Y, Nakatani K, Harada K et al. Stable expression of hif-1alpha in tubular epithelial cells promotes interstitial fibrosis. Am J Physiol Renal Physiol 2008; 295: F1023-F1029.
38. Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B et al. Hypoxia promotes fibrogenesis in vivo via hif-1 stimulation of epithelial-tomesenchymal transition. J Clin Invest 2007; 117: 3810-3820.
39. Schietke RE, Hackenbeck T, Tran M, Gunther R, Klanke B, Warnecke CL et al. Renal tubular hif-2alpha expression requires vhl inactivation and causes fibrosis and cysts. PLoS ONE 2012; 7: E31034.
40. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 2009; 30: 1073-1081.
41. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
42. Kraus S, Arber N. Inflammation and colorectal cancer. Curr Opin Pharmacol 2009; 9: 405-410.
43. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003; 3: 276-285.
44. Kundu JK, Surh YJ. Emerging avenues linking inflammation and cancer. Free Radic Biol Med 2012; 52: 2013-2037.
45. Larkin J, Goh XY, Vetter M, Pickering L, Swanton C. Epigenetic regulation in rcc: Opportunities for therapeutic intervention? Nat Rev Urol 2012; 9: 147-155.
46. Ibragimova I, Maradeo ME, Dulaimi E, Cairns P. Aberrant promoter hypermethylation of pbrm1, bap1, setd2, kdm6a and other chromatin-modifying genes is absent or rare in clear cell rcc. Epigenetics 2013; 8: 486-493.
47. Hakimi AA, Ostrovnaya I, Reva B, Schultz N, Chen YB, Gonen M et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators bap1 and setd2: A report by mskcc and the kirc tcga research network. Clin Cancer Res 2013; 19: 3259-3267.
48. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010; 463: 360-363.
49. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P et al. Exome sequencing identifies frequent mutation of the swi/snf complex gene pbrm1 in renal carcinoma. Nature 2011; 469: 539-542.
50. Kim N, Hong Y, Kwon D, Yoon S. Somatic mutaome profile in human cancer tissues. Genomics Inform 2013; 11: 239-244.
51. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C et al. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502: 333-339.
52. Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J et al. Genomewide association of hypoxia-inducible factor (hif)-1alpha and hif-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem 2009; 284: 16767-16775.
53. Haase VH, Glickman JN, Socolovsky M, Jaenisch R. Vascular tumors in livers with targeted inactivation of the von hippel-lindau tumor suppressor. Proc Natl Acad Sci USA 2001; 98: 1583-1588.
54. Tuominen VJ, Ruotoistenmaki S, Viitanen A, Jumppanen M, Isola J. Immunoratio: A publicly available web application for quantitative image analysis of estrogen receptor (er), progesterone receptor (pr), and ki-67. Breast Cancer Res 2010; 12: R56.